Natural‐Product‐Like Spiroketals and Fused Bicyclic Acetals as Potential Therapeutic Agents for B‐Cell Chronic Lymphocytic Leukaemia
- 8 December 2008
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 3 (12), 1922-1935
- https://doi.org/10.1002/cmdc.200800265
Abstract
B-cell chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in the Western world for which no curative treatments are currently available. Purine nucleotide analogues and alkylating agents feature frequently in combination regimens to treat the malignant state, but their use has not led to any significant improvement in patient survival. Consequently, there still remains a need for alternative small-molecule chemotherapeutics. Natural products are an unparalleled source of drug leads, and an unending inspiration for the design of small-molecule libraries for drug discovery. The screening of focused libraries of natural-product-like spiroketal and fused bicyclic acetal small molecules against primary CLL cells has led to the identification of a small series of novel and potent cytotoxic agents towards primary CLL cells. The validation of the activity of these molecules is delineated through a series of synthesis and screening iterations, whereas preliminary mode of action studies positively indicate their ability to induce cell death via an apoptotic pathway with no evidence of necrosis to further support their potential as novel chemotherapeutic agents.Keywords
This publication has 29 references indexed in Scilit:
- FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic LeukemiaThe Oncologist, 2008
- Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease EradicationClinical Cancer Research, 2008
- Emerging therapy for chronic lymphocytic leukaemiaBritish Journal of Haematology, 2007
- Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B‐cell chronic lymphocytic leukemiaCancer, 2007
- Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cellsBritish Journal of Cancer, 2007
- Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemiaBlood, 2006
- Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBlood, 2005
- Total Synthesis of Spongistatin 1: A Synthetic Strategy Exploiting Its Latent Pseudo‐SymmetryAngewandte Chemie, 2005
- The Novel Sequence-Specific DNA Cross-Linking Agent SJG-136 (NSC 694501) Has Potent and Selective In vitro Cytotoxicity in Human B-Cell Chronic Lymphocytic Leukemia Cells with Evidence of a p53-Independent Mechanism of Cell KillCancer Research, 2004
- Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemiaLeukemia, 2002